Combogesic Iv is a drug owned by Hikma Pharmaceuticals Usa Inc. It is protected by 5 US drug patents filed from 2023 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 14, 2036. Details of Combogesic Iv's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11213498 | Aqueous formulation comprising paracetamol and ibuprofen |
Jan, 2036
(11 years from now) | Active |
| US11389416 | Aqueous formulation comprising paracetamol and ibuprofen |
Jul, 2035
(10 years from now) | Active |
| US12083087 | Aqueous formulation comprising paracetamol and ibuprofen |
Jul, 2035
(10 years from now) | Active |
| US11446266 | Combination composition |
Oct, 2031
(6 years from now) | Active |
| US11896567 | Combination composition |
Oct, 2031
(6 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Combogesic Iv's patents.
Latest Legal Activities on Combogesic Iv's Patents
Given below is the list of recent legal activities going on the following patents of Combogesic Iv.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Patent eGrant Notification | 13 Feb, 2024 | US11896567 |
| Patent eGrant Notification | 13 Feb, 2024 | US11896567 |
| Patent Issue Date Used in PTA Calculation Critical | 13 Feb, 2024 | US11896567 |
| Recordation of Patent Grant Mailed Critical | 13 Feb, 2024 | US11896567 |
| Email Notification Critical | 13 Feb, 2024 | US11896567 |
| Recordation of Patent eGrant | 13 Feb, 2024 | US11896567 |
| Email Notification Critical | 25 Jan, 2024 | US11896567 |
| Issue Notification Mailed Critical | 24 Jan, 2024 | US11896567 |
| Application Is Considered Ready for Issue Critical | 16 Jan, 2024 | US11896567 |
| Dispatch to FDC | 16 Jan, 2024 | US11896567 |
FDA has granted several exclusivities to Combogesic Iv. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Combogesic Iv, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Combogesic Iv.
Exclusivity Information
Combogesic Iv holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Combogesic Iv's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 17, 2026 |
US patents provide insights into the exclusivity only within the United States, but Combogesic Iv is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Combogesic Iv's family patents as well as insights into ongoing legal events on those patents.
Combogesic Iv's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Combogesic Iv's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 14, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Combogesic Iv Generics:
There are no approved generic versions for Combogesic Iv as of now.
About Combogesic Iv
Combogesic Iv is a drug owned by Hikma Pharmaceuticals Usa Inc. It is used for managing moderate to severe pain in adults with the assistance of opioid analgesics. Combogesic Iv uses Acetaminophen; Ibuprofen Sodium as an active ingredient. Combogesic Iv was launched by Hikma in 2023.
Approval Date:
Combogesic Iv was approved by FDA for market use on 17 October, 2023.
Active Ingredient:
Combogesic Iv uses Acetaminophen; Ibuprofen Sodium as the active ingredient. Check out other Drugs and Companies using Acetaminophen; Ibuprofen Sodium ingredient
Treatment:
Combogesic Iv is used for managing moderate to severe pain in adults with the assistance of opioid analgesics.
Dosage:
Combogesic Iv is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1GM/100ML (10MG/ML);EQ 300MG BASE/100ML (EQ 3MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |